COMy 2021 | Treating elderly myeloma: frailty scoring and latest trial data
Meral Beksac, MD, Ankara University, Ankara, Turkey, shares the major topics discussed during the COMy 2021 session on therapy of elderly patients. Evidence presented at the COMy meeting demonstrated that myeloma in the elderly is often less aggressive than in younger patients, with a more slowly evolving disease course and more good risk features. However, high rates of frailty and comorbidities present challenges in the treatment of these patients. Dr Beksac outlines the IMWG frailty score and how this is being incorporated into clinical trials. Dr Beksac also shares the latest data from clinical trials assessing the treatment of elderly patients, particularly the promising efficacy findings for combined daratumumab-lenalidomide and dexamethasone. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Disclosures
Dr Beksac reports the following disclosures: participation in the CEPHEUS and IMROZ studies
